Skip to main content
. 2017 May 10;8(30):49548–49563. doi: 10.18632/oncotarget.17747

Figure 3. NKp30 recovery after CR is a better predictor of clinical outcome than NKp30 at diagnosis.

Figure 3

(A) The kinetics of NKp30 expression was assessed after CR (day 30, 60 and 90 after the last induction chemotherapy) in the IPC prospective cohort. Thirty-nine patients were tested for NKp30 expression at day 30, 28 patients at day 60 and 23 patients at day 90. The results were compared with NKp30 expression in healthy volunteers (N = 34) (B) Kinetics of NKp30 expression according to clinical outcome at 2 years. Kaplan-Meier estimates for overall survival (C) and relapse-free survival (D) by NKp30 expression at day 30 after induction chemotherapy in patients with intermediate cytogenetic prognosis (N = 28). Statistical analyses were performed using a Kruskal-Wallis test was used followed by a Dunn's post-test, and a log Rank tests for survival analyses. P < 0.05 was considered significant. 95%CI: 95% confidence interval; Diag: diagnosis; CR: complete remission; HR, hazard ratio; HV: healthy volunteers; ns: non significant.